$24.68
0.24[0.98%]
At close: Apr 26
$24.68
0[0.00%]
After Hours: 4:20PM EDT
Alkermes
(NASDAQ:ALKS)Latest News for Alkermes Stock (NASDAQ:ALKS)
Alkermes Stock (NASDAQ: ALKS)
Categories: All
Wednesday, April 24, 2024
Friday, April 19, 2024
Tuesday, April 09, 2024
- Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst SaysVandana Singh - Apr 9, 2024, 2:23PM
- Breaking Down Alkermes: 5 Analysts Share Their ViewsBenzinga Insights - Apr 9, 2024, 1:01PM
- Jefferies Maintains Buy on Alkermes, Raises Price Target to $50Benzinga Newsdesk - Apr 9, 2024, 12:07PM
- Alkermes shares are trading higher after the company announced topline results from its Phase 1b study of ALKS 2680 in patients with Narcolepsy Type 2 and Idiopathic Hypersomnia.Benzinga Newsdesk - Apr 9, 2024, 7:52AM
- Alkermes Announces Positive Topline Results From Phase 1b Study Of ALKS 2680 In Patients With Narcolepsy Type 2 And Idiopathic HypersomniaBenzinga Newsdesk - Apr 9, 2024, 7:03AM
Monday, April 08, 2024
Monday, April 01, 2024
Tuesday, March 19, 2024
Monday, March 11, 2024
Thursday, February 15, 2024
- Alkermes shares are trading higher after the company reported mixed Q4 results and approved a share repurchase program of up to $400 million.Benzinga Newsdesk - Feb 15, 2024, 11:37AM
- Alkermes Expects Fiscal Year 2024 Revenues Of $1.5B-$1.6B Versus Consensus Of $1.52B And Expects to Generate 30% EBITDA Margin in 2024Benzinga Newsdesk - Feb 15, 2024, 7:19AM
- Alkermes' Board Of Directors Approved A New Share Repurchase Program, Authorizing The Company To Repurchase Up To $400MBenzinga Newsdesk - Feb 15, 2024, 7:17AM
- Alkermes Q4 Adjusted EPS $0.48 Misses $0.51 Estimate, Sales $377.48M Beat $362.02M EstimateBenzinga Newsdesk - Feb 15, 2024, 7:02AM
- Earnings Scheduled For February 15, 2024Benzinga Insights - Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
Tuesday, January 02, 2024
Thursday, December 14, 2023
Monday, November 20, 2023
Wednesday, November 15, 2023
Thursday, October 26, 2023
Wednesday, October 25, 2023
- Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Oct 25, 2023, 1:49PM
- Alkermes shares are trading lower following Q3 results.Benzinga Newsdesk - Oct 25, 2023, 11:44AM
- Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 OutlookLekha Gupta - Oct 25, 2023, 11:09AM
- Earnings Scheduled For October 25, 2023Benzinga Insights - Oct 25, 2023, 7:32AM
- Alkermes Q3 Adj EPS $0.64 Beats $0.43 Estimate, Sales $380.94M Beat $362.15M EstimateBenzinga Newsdesk - Oct 25, 2023, 7:09AM
Tuesday, October 24, 2023
Monday, October 23, 2023
Tuesday, October 17, 2023
Wednesday, August 30, 2023
- Alkermes shares are trading higher after the company announced it entered into a settlement agreement with Teva Pharmaceuticals related to VIVITROL patent litigation.Benzinga Newsdesk - Aug 30, 2023, 12:25PM
- Hovnanian Enterprises, LexinFintech Holdings And Other Big Stocks Moving Higher On WednesdayLisa Levin - Aug 30, 2023, 10:37AM
- Alkermes Announces Settlement With Teva Related to VIVITROL Patent LitigationBenzinga Newsdesk - Aug 30, 2023, 7:25AM
- Alkermes Settles Patent Litigation With Teva Pharmaceuticals Related To Vivitrol (Naltrexone For Extended-release Injectable Suspension). Teva Can Market A Generic Version Of Vivitrol In The US Beginning January 15, 2027Benzinga Newsdesk - Aug 30, 2023, 7:12AM
Thursday, August 17, 2023
Thursday, July 27, 2023
Wednesday, July 26, 2023
- Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting InvegaVandana Singh - Jul 26, 2023, 11:58AM
- Alkermes Q2 Adjusted EPS $0.55 Misses $0.56 Estimate, Sales $617.40M Beat $585.02M EstimateBenzinga Newsdesk - Jul 26, 2023, 7:02AM
- Earnings Scheduled For July 26, 2023Benzinga Insights - Jul 26, 2023, 4:18AM